A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]

Tauber J, Schechter BA, Bacharach J, et al. Clin Ophthalmol. 2018;12:1921–1929.On page 1927, “Safety and tolerability assessments” section, third paragraph, first sentence should read from “Fifteen subjects exited the study due to AE...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tauber J, Schechter BA, Bacharach J, Toyos MM, Smyth-Medina R, Weiss SL, Luchs JI
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/e9176c7786504f4eb8f64329f3734daf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e9176c7786504f4eb8f64329f3734daf
record_format	dspace
spelling	oai:doaj.org-article:e9176c7786504f4eb8f64329f3734daf2021-12-02T06:08:15ZA Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]1177-5483https://doaj.org/article/e9176c7786504f4eb8f64329f3734daf2019-01-01T00:00:00Zhttps://www.dovepress.com/corrigendum2-a-phase-iiiii-randomized-double-masked-vehicle-contr-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Tauber J, Schechter BA, Bacharach J, et al. Clin Ophthalmol. 2018;12:1921–1929.On page 1927, “Safety and tolerability assessments” section, third paragraph, first sentence should read from “Fifteen subjects exited the study due to AEs: 5 subjects (3.3%) in the OTX-101 0.09% group, 4 subjects (2.6%) in the OTX-101 0.09% group, and 6 subjects (3.9%) in the vehicle group.” to “Fifteen subjects exited the study due to AEs: 5 subjects (3.3%) in the OTX-101 0.09% group, 4 subjects (2.6%) in the OTX-101 0.05% group, and 6 subjects (3.9%) in the vehicle group.”Read the original articlePrevious corrigendum has been publishedTauber JSchechter BABacharach JToyos MMSmyth-Medina RWeiss SLLuchs JIDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 13, Pp 215-216 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Tauber J Schechter BA Bacharach J Toyos MM Smyth-Medina R Weiss SL Luchs JI A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]
description	Tauber J, Schechter BA, Bacharach J, et al. Clin Ophthalmol. 2018;12:1921–1929.On page 1927, “Safety and tolerability assessments” section, third paragraph, first sentence should read from “Fifteen subjects exited the study due to AEs: 5 subjects (3.3%) in the OTX-101 0.09% group, 4 subjects (2.6%) in the OTX-101 0.09% group, and 6 subjects (3.9%) in the vehicle group.” to “Fifteen subjects exited the study due to AEs: 5 subjects (3.3%) in the OTX-101 0.09% group, 4 subjects (2.6%) in the OTX-101 0.05% group, and 6 subjects (3.9%) in the vehicle group.”Read the original articlePrevious corrigendum has been published
format	article
author	Tauber J Schechter BA Bacharach J Toyos MM Smyth-Medina R Weiss SL Luchs JI
author_facet	Tauber J Schechter BA Bacharach J Toyos MM Smyth-Medina R Weiss SL Luchs JI
author_sort	Tauber J
title	A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]
title_short	A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]
title_full	A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]
title_fullStr	A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]
title_full_unstemmed	A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]
title_sort	phase ii/iii, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of otx-101 in the treatment of dry eye disease [corrigendum]
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/e9176c7786504f4eb8f64329f3734daf
work_keys_str_mv	AT tauberj aphaseiiiiirandomizeddoublemaskedvehiclecontrolleddoserangingstudyofthesafetyandefficacyofotx101inthetreatmentofdryeyediseasecorrigendum AT schechterba aphaseiiiiirandomizeddoublemaskedvehiclecontrolleddoserangingstudyofthesafetyandefficacyofotx101inthetreatmentofdryeyediseasecorrigendum AT bacharachj aphaseiiiiirandomizeddoublemaskedvehiclecontrolleddoserangingstudyofthesafetyandefficacyofotx101inthetreatmentofdryeyediseasecorrigendum AT toyosmm aphaseiiiiirandomizeddoublemaskedvehiclecontrolleddoserangingstudyofthesafetyandefficacyofotx101inthetreatmentofdryeyediseasecorrigendum AT smythmedinar aphaseiiiiirandomizeddoublemaskedvehiclecontrolleddoserangingstudyofthesafetyandefficacyofotx101inthetreatmentofdryeyediseasecorrigendum AT weisssl aphaseiiiiirandomizeddoublemaskedvehiclecontrolleddoserangingstudyofthesafetyandefficacyofotx101inthetreatmentofdryeyediseasecorrigendum AT luchsji aphaseiiiiirandomizeddoublemaskedvehiclecontrolleddoserangingstudyofthesafetyandefficacyofotx101inthetreatmentofdryeyediseasecorrigendum AT tauberj phaseiiiiirandomizeddoublemaskedvehiclecontrolleddoserangingstudyofthesafetyandefficacyofotx101inthetreatmentofdryeyediseasecorrigendum AT schechterba phaseiiiiirandomizeddoublemaskedvehiclecontrolleddoserangingstudyofthesafetyandefficacyofotx101inthetreatmentofdryeyediseasecorrigendum AT bacharachj phaseiiiiirandomizeddoublemaskedvehiclecontrolleddoserangingstudyofthesafetyandefficacyofotx101inthetreatmentofdryeyediseasecorrigendum AT toyosmm phaseiiiiirandomizeddoublemaskedvehiclecontrolleddoserangingstudyofthesafetyandefficacyofotx101inthetreatmentofdryeyediseasecorrigendum AT smythmedinar phaseiiiiirandomizeddoublemaskedvehiclecontrolleddoserangingstudyofthesafetyandefficacyofotx101inthetreatmentofdryeyediseasecorrigendum AT weisssl phaseiiiiirandomizeddoublemaskedvehiclecontrolleddoserangingstudyofthesafetyandefficacyofotx101inthetreatmentofdryeyediseasecorrigendum AT luchsji phaseiiiiirandomizeddoublemaskedvehiclecontrolleddoserangingstudyofthesafetyandefficacyofotx101inthetreatmentofdryeyediseasecorrigendum
_version_	1718400085404942336

A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]

Ejemplares similares